Experimental chemo cocktail targets resistant leukemia
NCT ID NCT03150004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of chemotherapy drugs (cladribine, cytarabine, mitoxantrone, and G-CSF) in 53 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that had come back or not responded to prior treatment. The goal was to see how many patients achieved complete remission with no detectable cancer cells. However, the trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cladribine, cytarabine, mitoxantrone, and G-CSF (CLAG-M regimen)
What this could lead to
If successful, this could offer a treatment option for people with hard-to-treat leukemia or MDS who have not responded to other therapies.
What could go wrong
The trial was terminated early, so results are limited. It is a small, single-center study, and the chemotherapy has significant side effects like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States